Jaguar Health to Hold Investor Webcast November 17 Regarding Q3 2026 Financials & Corporate Updates

Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) will hold an investor webcast on November 17, 2026, to review third-quarter financials and provide corporate updates. The webcast begins at 8:30 a.m. Eastern and covers the third quarter of 2026. A replay will be available in the investor relations section of Jaguar's website.

Key Terms

microvillus inclusion disease, short bowel syndrome

2 terms

microvillus inclusion disease medical

"microvillus inclusion disease and short bowel syndrome"

A rare, inherited condition in which the tiny, brush-like hairs on the inner lining of the small intestine are absent or abnormal, causing severe, lifelong diarrhea and inability to absorb nutrients. Think of the intestine’s surface as a shaggy carpet that helps soak up food; when those fibers are missing or disorganized, patients often need long-term intravenous feeding and specialized care. For investors, the disease matters because it creates clear demand for diagnostics, nutritional support, transplant solutions, and targeted therapies in the orphan-disease market.

short bowel syndrome medical

"microvillus inclusion disease and short bowel syndrome"

A chronic digestive disorder caused when a large portion of the small intestine is missing or not working, so the body cannot absorb enough nutrients and fluids from food. Investors should care because people with this condition often need long-term medical treatments, specialized nutrition or surgeries, and ongoing devices or drugs, creating sustained demand, higher healthcare costs, and opportunities for companies that provide therapies, supplies, or related services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, CA / ACCESS Newswire / November 13, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Tuesday, November 17, 2026 at 8:30 a.m. Eastern to review third-quarter 2026 financials and provide corporate updates.

Participation Instructions for Jaguar Health Investor Webcast

When: Tuesday, November 17, 2026 at 8:30 a.m.

Participant Registration & Access Link: Click Here

Replay: A replay of the webcast will be available on the investor relations section of Jaguar's website: (click here)

About the Jaguar Health Family of Companies

Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar will file its Form 10-Q on November 16, 2026 for the quarter ended September 30, 2026, and the expectation that Jaguar will hold an investor webcast on November 17, 2026. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire